Sentence examples for current manufacturing capacity from inspiring English sources

Qualcomm is currently manufacturing the devices at sizes of about a meter squared at a plant in Taiwan, but the company would not comment on their current manufacturing capacity.

For example, the following sentence has two topical themes, "our plant capacity" in the first clause and an ellipsed one in the second, in addition to the textual theme 'and': "Our plant capacity is expected to experience a growth and will require re-assessment and evaluation of our current manufacturing capacity".

Current manufacturing capacity is insufficient to produce the vaccines within a few months following declaration of an influenza pandemic [ 20].

Thus, it may be concluded that the current manufacturing capacity within South Africa is sufficient to accommodate likely increases in demand from the aquafeed sector.

Considering the current manufacturing capacity estimated at 1420 million doses [ 21], it would be necessary to increase by a factor of 1.5 the current capacity to supply the world's population within 1 year.

A comparison with the current production capacity (during 2000, the formal feed industry produced 4.5 million tonnes of feed) suggests that even at a 10percentt annual expansion of the aquaculture sector, the aquafeed requirements in 2015 will represent less than 0.2percentt of the country's current manufacturing capacity.

Production of quadrivalent vaccines could help maintain the current global manufacturing capacity, which would also enhance pandemic preparedness since the capacity could be redirected to manufacture monovalent pandemic doses.

"However, current limitations of global vaccine manufacturing capacity, drug production and stockpiling," the plan says, "and limited stocks of relevant medical equipment, will make it extremely difficult, if not impossible, to provide any materials from any one country".

Even though numerical optimization technique may serve as an excellent material tailoring tool, the capacity of current manufacturing techniques of FGM may not yield the target volume fraction.

The company just received an $8 million Series A funding round led by Lux Capital, along with SoftTech, AME, and Bolt, to help improve its current manufacturing facility, which is already at capacity.

Since no genetic adaptation of the virus is needed and only the HA sequence from the new strain is required to initiate vaccine production, this plant-based platform is an interesting alternative to current technologies to increase global vaccine manufacturing capacity.